Muhammad Awidi, Assistant Professor of Medicine at the West Virginia University School of Medicine, shared on LinkedIn:
“Honored to be invited by the NEJM Group to write the Clinical Oncology Topic Update on a subject close to my heart.
Patients who develop malignancy after a solid-organ transplant have historically been excluded from clinical trials.
This review tackles the complex challenge of using immune checkpoint inhibitors in this vulnerable population—specifically weighing the organ-specific risks and balancing immunity against graft tolerance.
If you would like to read the full update, feel free to send me a direct message and I’ll gladly share the PDF copy with you!”
More posts featuring Muhammad Awidi.